MedTrace Logo

Psychological Mobile App for Patients With AML

NCT05501171 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-08-02

No results posted yet for this study

Summary

This research study is evaluating whether a psychological mobile application (app), is efficacious in reducing anxiety and depression symptoms and improving quality of life for patients diagnosed with acute myeloid leukemia (AML) compared to a physical health promotion app.

Conditions

Interventions

BEHAVIORAL

DREAMLAND

DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on: 1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance. 2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support. 3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty. 4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care. Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete. Other names BNT200

BEHAVIORAL

CERENA

CERENA is a self-administered physical health app that includes 4 modules focused, focused on: 1. Education about general wellness. 2. Nutrition. 3. Exercise. 4. Cancer prevention. Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete.

Sponsors & Collaborators

  • Blue Note Therapeutics

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Areej El-Jawahri, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-15
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05501171 on ClinicalTrials.gov